Status:
COMPLETED
Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- HbA1C = 7.5%
- Insulin naïve
- Current treatment by Oral Anti-diabetic Drugs
Exclusion
- Severe medical conditions
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
321 Patients enrolled
Trial Details
Trial ID
NCT00184561
Start Date
July 1 2005
End Date
July 1 2006
Last Update
January 6 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100029
2
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100730
3
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China, 510120
4
Novo Nordisk Investigational Site
Wuhan, Hubei, China, 430022